
Andrea Resovi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2183968/publications.pdf Version: 2024-02-01



ANDREA RESOVI

#	Article	IF	CITATIONS
1	Current understanding of the thrombospondin-1 interactome. Matrix Biology, 2014, 37, 83-91.	3.6	228
2	Soluble stromaâ€related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	6.9	56
3	Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFÎ ² and in cooperation with PDGF. Matrix Biology, 2016, 55, 106-116.	3.6	52
4	Targeting angiogenesis with compounds from the extracellular matrix. International Journal of Biochemistry and Cell Biology, 2011, 43, 1674-1685.	2.8	36
5	Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. Oncogene, 2016, 35, 6212-6222.	5.9	35
6	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	5.3	28
7	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. Cells, 2020, 9, 952.	4.1	23
8	Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Scientific Reports, 2016, 6, 23432.	3.3	20
9	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connective Tissue Research, 2015, 56, 355-363.	2.3	10
10	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. Cancers, 2020, 12, 2312.	3.7	5
11	Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice. Cancers, 2022, 14, 1814.	3.7	3
12	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36.	3.6	2
13	Abstract B12: Circulating stroma-related molecules as potential biomarkers for pancreatic ductal adenocarcinoma. , 2015, , .		0
14	Abstract 3857: Patient-derived tumor xenografts as pharmacological model of human pancreatic ductal adenocarcinoma. , 2017, , .		0
15	Abstract 2981: Identification of circulating stroma-related biomarkers for pancreatic ductal adenocarcinoma. , 2017, , .		Ο
16	Abstract 198: The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature. , 2019, , .		0